Sherwin D'souza, MD
Internal Medicine · Pocatello, IDNPI 1225061351
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $332,456 of the $542,925 with a category attached, or 61.2%. 34 manufacturers reported payments, led by Novo Nordisk at 38.0% of the total. Among internal medicine clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 976 payments — averaging $556.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$206K
- Lilly USA, LLC$140K
- Amgen$57K
- Eli Lilly$52K
- Madrigal Pharmaceuticals$34K
- Novo Nordisk AS$15K
- plus $39K from 28 others
Across 37 payments — averaging $11,191 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$412K
- Eli Lilly Export S.A. Puerto Rico Branch$2K
What the payments were for
- Consulting fees$126,98723%
- Speaking & faculty fees$332,45661%
- Travel & lodging$62,31511%
- Food & beverage$20,9504%
- Education$2170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 256 | $206,066 |
| Lilly USA, LLC | 238 | $139,719 |
| Amgen(2 entities) | 102 | $57,177 |
| Eli Lilly | 103 | $51,749 |
| Madrigal Pharmaceuticals | 52 | $34,329 |
| Novo Nordisk AS | 6 | $15,358 |
| AstraZeneca(2 entities) | 30 | $12,877 |
| Bayer | 20 | $9,814 |
| Boehringer Ingelheim | 12 | $4,943 |
| Dexcom, Inc. | 16 | $4,313 |
| Corcept Therapeutics | 15 | $1,860 |
| Novartis | 13 | $1,095 |
| Insulet Corporation | 16 | $673 |
| Medtronic(2 entities) | 12 | $650 |
| Tandem Diabetes Care, Inc. | 14 | $607 |
| Abbott | 18 | $536 |
| Sanofi-aventis U.S. LLC | 14 | $269 |
| Ascendis Pharma Endocrinology Inc | 7 | $186 |
| Recordati_rare_diseases_inc. | 6 | $148 |
| Xeris Pharmaceuticals, Inc. | 4 | $78 |
| Shire North American Group Inc | 1 | $60 |
| Johnson & Johnson(2 entities) | 2 | $54 |
| Pfizer | 3 | $48 |
| Senseonics, Incorporated | 2 | $46 |
| IBSA Pharma Inc. | 2 | $42 |
| Merck | 3 | $42 |
| AbbVie | 2 | $36 |
| Rhythm Pharmaceuticals, Inc. | 1 | $34 |
| Averitas Pharma Inc. | 1 | $27 |
| EUSA Pharma (US) LLC | 1 | $23 |
| BETA Bionics, Inc. | 1 | $20 |
| Echosens North America, Inc. | 1 | $17 |
| Companion Medical, Inc. | 1 | $15 |
| Zealand Pharma US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$128,037
- RYBELSUS$60,909
- Ozempic$50,971
- TEPEZZA$48,531
- Tresiba$45,443
- REZDIFFRA$32,571
- FARXIGA$11,606
- Kerendia$9,496
- JARDIANCE$6,943
- DEXCOM G6 CGM SYSTEM$2,964
- Korlym$1,633
- DEXCOM CGM$1,050
- LEQVIO$457
- t:slim X2 Insulin Pump with Control-IQ$239
- Victoza$185
- Xultophy 100/3.6$185
- MINIMED 780G$184
- InPen$160
- FREESTYLE LIBRE 3$158
- Fabhalta$139
How this compares
$542,925 in reported general payments places this provider in the 95th percentile of 289 internal medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 513 | $459,991 |
| OzempicSemaglutide | 161 | $204,485 |
| MycapssaOctreotide Acetate | 12 | $150,318 |
| JardianceEmpagliflozin | 78 | $87,703 |
| MounjaroTirzepatide | 72 | $83,373 |
| NexletolBempedoic Acid | 76 | $74,776 |
| VascepaIcosapent Ethyl | 84 | $69,605 |
| Praluent PenAlirocumab | 72 | $59,219 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $36,743 |
| SandostatinOctreotide Acetate | 12 | $30,313 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $30,044 |
| FarxigaDapagliflozin Propanediol | 46 | $29,049 |
| Humalog Kwikpen U-200Insulin Lispro | 13 | $27,655 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 21 | $24,107 |
| Repatha SyringeEvolocumab | 30 | $21,799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $206,066 | $213,407193 claims |
| Lilly USA, LLCMounjaro, Humalog, Insulin Lispro | $139,719 | $95,371124 claims |
| Boehringer IngelheimJardiance | $4,943 | $87,70378 claims |
| NovartisSandostatin | $1,095 | $30,31312 claims |
| AstraZenecaFarxiga | $12,877 | $29,04946 claims |
| AbbVieSynthroid | $36 | $2,82334 claims |
| Sanofi-aventis U.S. LLCLantus | $269 | $2,59413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 289 internal medicine providers in Idaho.
Other internal medicine in Pocatello
- Aditya SinghPocatello$37K
- Douglas AndersenPocatello$7K
- Gabriela AnghelPocatello$1K
- Shawn AllmanPocatello$624
- Trey RogersPocatello$495
- Victor LiuPocatello$312
- Diana DumitrascuEagle$143K
- Huiling QiBoise$62K
- Carolyn BridgesBoise$27K
- Susan WachterIdaho Falls$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.